KUALA LUMPUR, Oct 10 (Bernama) -- Shanghai UniCAR-Therapy Bio-Medicine Technology Co selected Terumo BCT and its cell expansion devices to automate its cell therapy manufacturing process for chimeric antigen receptor (CAR) T- cell therapies.
UniCAR will also open their Center of Excellence for Terumo BCT’s technologies in November in Shanghai, a statement said.
Senior Vice President, Global Commercial at Terumo BCT, Cindy Ng said the science and development in the cell and gene therapy space are rapidly evolving and the collaboration with UniCAR has the potential to touch many patients’ lives.
Terumo BCT is a global leader in blood component, therapeutic apheresis and cellular therapy technologies. It provides flexible solutions for CAR T-cell developers and manufacturers, including the Quantum Cell Expansion System which is currently used in UniCAR.
The company continues to deliver high-levels of service to support its customer’s innovations including its latest technology in development -- The Finia Fill and Finish System -- which designed to automate the final step of cell processing.
Terumo BCT is the only company with the unique combination of apheresis collections, manual and automated whole blood processing and pathogen reduction technologies. More details on https://www.terumobct.com.
-- BERNAMA
No comments:
Post a Comment